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ABSTRACT  
Fibrodysplasia Ossificans Progressiva (FOP) is a rare 
monogenetic disorder in which patients develop 
heterotopic ossification (HO). A heterozygous mutation 
in BMP type I receptor ALK2 results in hyper-sensitized 
BMP signaling. The aim of this study is to identify small 
molecules which can selectively inhibit this overactive 
BMP pathway. Thirteen FDA-approved small molecules 
were tested on their effect on BMP6-induced target gene 
expression, alkaline phosphatase activity and 
mineralization in KS483 cells. We identified 
cryptotanshinone as a small molecule able to inhibit BMP 
signaling. In conclusion, cryptotanshinone could be a 
novel small molecule inhibitor of the overactive BMP 
signaling pathway in FOP. 
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INTRODUCTION 
Fibrodysplasia Ossificans Progressiva (FOP) is a rare 
genetic disease affecting only 1 in 2 million people 
worldwide. Trauma, injury or other inflammatory-related 
events induce so-called ‘flare-ups’ during which FOP 
patients develop extra-skeletal bone in connective tissues, 
a process called heterotopic ossification (HO).1 
The clinical presentation of FOP patients is caused by a 
heterozygous mutation in the ACVR1 gene which encodes 
for the BMP type I receptor ALK2 (Figure 1).2 This 
mutation is located in the ‘GS-domain’ of the ALK2 
receptor and causes the receptor to be no longer inhibited, 
but stimulated by Activin A.3 This genetic deficit thus 
leads to overactive BMP signaling which in combination 
with inflammation results in heterotopic ossification.  
Since surgical resection of extra skeletal bone lead to 
counterproductive results, current therapies focus on the 
prevention of the harmful flare-up periods by education, 
influenza vaccination and glucocorticosteroids 
administration. Recently, several other therapeutic 
strategies have been examined for the treatment of FOP.  
Small interfering RNAs and Antisense oligonucleotides 
(AONs) have been developed to specifically target the 
mutated ALK2.4 The feasibility of safe transfer of these 
RNAs in humans, however, is still under debate. A 
curative therapy for the heterotopic ossification has thus 
not been identified yet. 
Treatment of heterotopic ossification could be established 
by novel small molecule inhibitors. Palovarotene, a small 
molecule RAR-γ agonist, is currently being evaluated in a 
clinical trial for the treatment of FOP. Major concerns 
about this treatment, however, are the long-lasting effects 
of RAR-γ agonists on growth plates of children with 
FOP.5  
Also, several small molecule inhibitors of the ALK2 
receptor have already been developed. LDN-193189 
targets ALK2 and has a higher specificity for this receptor 
than his precursor dorsomorphin.6 Further optimization of 
the dorsomorphin-derivatives resulted in the identification 
of the third generation ALK2 inhibitor LDN-212854. 
LDN-212854 has a much higher specificity for ALK2 in 
comparison with other BMP and TGF-β receptors than 
LDN-193189.7 The major disadvantage of the 
dorsomorphin-like small molecule kinase inhibitors, 
however, is their lack of specificity.8 Small molecule 
inhibitors that target kinases downstream of ALK2 could 
potentially circumvent these harmful off-target effects. 
In conclusion, the aim of this study is to identify a novel 
small molecule BMP inhibitor for the treatment of HO in 
FOP. By only screening small molecules which clinical 
use is approved by the Food and Drug Administration 
(FDA) identified small molecules could be readily 
translated into the clinic of FOP patients. 
METHODS 
All experiments were performed on KS483 mouse bone-
forming precursor cells (osteoblasts). For the last 
experiment, endothelial precursor cells obtained from 
FOP patients were used. Cells treated with only solvent 
DMSO (10 μM) were used as a positive control. Small 
molecule ALK2 inhibitor LDN-193189 (120 nM) treated 
cells functioned as a negative control.  
Cell culture 
Mouse osteoblast progenitor cells KS483 were cultured in 
Alpha Minimal Essential Medium (α-MEM) + 
GlutaMAX™ (Gibco) with 10% fetal bovine serum 
(Gibco) and 0.4% penicillin/streptomycin (Invitrogen). 
EBM-2 (Lonza) supplemented with 10% FBS (Gibco) 
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 and 0.4% penicillin/streptomycin (Invitrogen) was used 
to culture FOP-patient-derived endothelial precursor 
cells. Cells were grown at 37°C and 5% CO2. Medium 
was changed every three or four days.  
 
 
 
Quantitative PCR [1] 
BMP6 (50 ng/mL), a ligand for ALK2, was used to 
stimulate the BMP signaling pathway in KS483 cells for 
6 hours. As a result of BMP receptor stimulation, BMP 
target genes (Id1, Id3) are more transcribed into mRNAs. 
We measured the effect of half an hour pretreatment with 
small molecules (10 μΜ) on the abundance of Id1 and Id3 
mRNAs in a quantitative PCR. The housekeeping gene 
HPRT1 was used to normalize the Id1 and Id3 gene 
expression data. 
 
 
 
 
Alkaline phosphatase (ALP) assay [2] 
By stimulating the osteoblast precursor cells with BMP6 
(50 ng/mL) for three days, these KS483 cells can change 
(differentiate) into bone forming cells. An early marker of 
osteoblast differentiation, is the formation of phosphates 
by an enzyme called alkaline phosphatase. By adding p-
nitrophenyl phosphate (PNPP) solution (Thermo 
Scientific™ Pierce™) the effect on small molecules on 
BMP6-induced ALP activity was measured at 405 nm. 
Mineralization assay [3] 
The actual formation of calcium deposits (bone) can be 
measured with a Mineralization assay. KS483 cells were 
stimulated with BMP6 (50 ng/mL), small molecules and 
ALP substrates, ascorbic acid and β-glycerolphosphate 
for six days. An Alizarin Red (Sigma) staining was 
performed to visualize the calcium deposits. 
Cetylpyridinium chloride was used to extract the staining 
in a quantifiable solution. Absorbance was measured at 
545 nm. 
Quantification and statistical methods 
For staining quantification of the mineralization and 
alkaline phosphatase assay the absorption of the cell 
lysate was measured by a plate reader. All statistical 
analyses were performed using Student’s t-tests. A p-
value of less than 0.05 was considered significant. 
RESULTS 
Seven small molecules inhibited BMP target gene 
expression without cell toxicity 
Thirteen FDA-approved small molecules listed in Table 
1 were selected by a pre-screening and included in this 
screening. First, the effect of the small molecules on 
BMP-target gene expression was measured in a 
quantitative PCR.  
 
 
 
 
Figure 2 The effect of compounds on BMP6-induced target gene expression in an initial screening of KS483 cells. KS483 cells 
were pretreated with 10 µM compound for half an hour and stimulated with BMP6 (50 ng/mL) for six hours. CS, CT, JLS-17, 
JLS-18, MC, MD and SM inhibited Id1 and Id3 gene expression. (n=1) 
 
Figure 1 An overview of the used methods: qPCR [1], ALP 
assay [2] and Mineralization assay [3].9 
All KS483 cells were stimulated with BMP6 (50 ng/mL), 
except the non-treated BLANK condition. DMSO was 
used as a vehicle control and ALK2 inhibitor, LDN-
193189 as a negative control. As Figure 2 shows, seven 
of the thirteen compounds (e.g., CS, CT, JLS17, JLS18, 
MC, MD, SM) potently inhibited both BMP6-induced Id1 
and Id3 gene expression in mouse osteoblast progenitor 
KS483 cells. Cryptotanshinone (CS), cantharadin (CT), 
miconazole nitrate (MC), moxidectin (MD), selamectin 
(SM), JLS-17 and JLS-18 also did not show a major 
effect on KS483 cell proliferation in a MTS assay (Data 
not shown).   
 
 
 
 
 
 
 
 
Cryptotanshinone dose-dependently inhibits 
osteoblast differentiation 
Because of its potency of inhibiting BMP6 target gene 
expression and BMP6-induced ALP activity and 
mineralization (Data not shown) without cell toxicity, we 
selected cryptotanshinone (CS) as the most promising 
candidate. As Figure 4 shows, CS dose-dependently 
inhibited ALP activity in KS483 cells. ALK2 inhibitor 
LDN-193189, 2.5 and 5.0 μM of CS significantly 
inhibited ALP activity in comparison to vehicle control 
DMSO. Also, mineralization was potently inhibited by 
CS on a dose-dependent manner; 5.0 and 10.0 μM of CS 
reduced mineralization significantly (Figure 5).  
 
 
 
 
The effect of cryptotanshinone on FOP patient-
derived cells 
In order to assess the effect of CS on FOP patient-derived 
cells, endothelial precursor cells obtained from patients 
were tested in a mineralization assay. In an experimental 
design, comparable to the KS483 cells, the endothelial 
precursor cells were stimulated with low dose CS (1.0, 
2.5 or 5.0 µM), BMP6 (50 ng/Ml) and osteogenic 
medium for seven days. Unexpectedly, cryptotanshinone 
was cell-toxic in these FOP patient-derived endothelial 
precursor cells. The cells cultured in normal medium and 
the cells treated with BMP6, osteogenic medium and 
ALK2 inhibitor LDN-193189 didn’t show cell death.  
CONCLUSION 
Because small molecules could be attractive therapeutics 
for inhibiting the overactive BMP signaling pathway in 
FOP, we performed a screening of thirteen FDA- 
approved small compounds. From this screening 
cryptotanshinone (CS) was selected as the best candidate 
based on its inhibiting effects on osteoblast differentiation 
without cell-toxic effects on KS483 cells. 
Cryptotanshinone decreased BMP6-induced target gene 
expression, ALP activity and mineralization. Low dose 
CS was also able to induce to induce cell-death in 
endothelial precursor cells derived from FOP patients.  
CS, a tanshinone isolated from the traditional Chinese 
herb Salvia miltiorrhiza, has been reported to have 
several effects on major cell processes. It has been shown 
to induce apoptosis in multiple tumor cell lines in vitro.10 
Also, several studies suggest that patients with cognitive 
impairment (Alzheimer’s disease, insomnia e.g.) might 
benefit from treatment with CS because of its 
acetylcholine esterase inhibiting properties.11  
Furthermore, CS inhibits the inflammatory related TNF-α 
and LPS-induced signal transduction pathways in several 
cell types.12 If CS simultaneously inhibits inflammatory 
pathways and the BMP signaling pathway, CS treatment 
could potentially act as a double-edge sword by reducing 
the inflammatory-related flare-ups and inhibiting the 
overactive BMP signaling pathway in FOP patients. 
We show that CS inhibited the overactive BMP signaling 
pathway in a mouse cell line with osteogenic properties. 
However, endothelial cells have been shown to give rise 
to the largest portion of cells infiltrating heterotopic 
ossification sites in a lineage tracing study of a FOP 
mouse model.13 Therefore, we believe that the use of 
unique FOP patient-derived endothelial cells in long term 
differentiation assays is an excellent in vitro model for 
the assessment of BMP-inhibiting properties of small 
molecules. CS induced apoptosis in FOP patient-derived 
endothelial precursor cells which can thus reduce the 
amount of infiltrate on the heterotopic ossification sites. It 
is, however, likely that the induction of apoptosis by CS 
is not limited to these harmful infiltrating cells. By 
restricting the CS treatment to topical administration 
during flare-ups, we could diminish the side-effects of the 
CS treatment. Nevertheless, the cell-toxicity of CS should 
be assessed in multiple human cell lines in future 
research.  
Figure 4 The effect of CS on ALP activity in KS483 cells. 
2.5 and 5.0 μM significantly inhibited ALP activity. 10 μM 
was cell-toxic in this assay. (n = 3) p < 0.05 = *, p < 0.01 = 
**, p < 0.001 = *** 
  
CS might be more specific than ALK2 inhibitors and the 
RAR-γ agonist currently evaluated in a clinical trial, 
because it has the potential to specifically inhibit 
mineralization induced by flare-ups. However, the exact 
mechanism via which CS exerts its function is unclear. In 
conclusion, we identified cryptotanshinone as a novel 
BMP inhibitor for the treatment of FOP. 
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Figure 5 Titrate curve of CS in a mineralization assay in 
KS483 cells. Figure 5 shows the quantification of the 
Alizarin Red staining. CS 5.0 and 10 µM concentrations 
significantly inhibited mineralization. (n = 3 for LDN-
193189, CS 2.5 and CS 5.0, n = 6 for BLANK, DMSO, CS 
1.0 and CS 10.0) 
